BioMarin Pharmaceutical Inc. filed a current report on Form 8-K on August 18, 2026, disclosing that it entered into a Share Purchase Agreement on August 17, 2026, to acquire Alesta Therapeutics B.V., a private Dutch rare disease company, for an upfront payment of $275 million plus up to $215 million in contingent milestone payments.

Key Highlights

  • Upfront consideration: BioMarin agreed to pay $275 million in cash at closing, subject to a customary post-closing purchase price adjustment.
  • Milestone payments: Up to $215 million in additional future payments are contingent on the achievement of various development milestones.
  • Transaction structure: The acquisition is structured as a cash-free, debt-free share purchase transaction.
  • Target company: Alesta Therapeutics B.V. is a private company headquartered in the Netherlands that develops novel oral small molecule therapies for underserved rare diseases.
  • Expected closing: The Share Purchase is expected to be completed in the third quarter of calendar year 2026, subject to certain closing conditions.
  • Pre-closing requirement: Closing conditions include the completion of a pre-closing transfer of certain of Alesta's assets and businesses to Anaheim SpinCo B.V.

BioMarin's Share Purchase Agreement for Alesta Therapeutics: Key Terms and Conditions

According to the filing, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) entered into the Share Purchase Agreement on August 17, 2026, with Alesta Therapeutics B.V., the holders of Alesta shares identified on Schedule 1.1(a) to the Purchase Agreement, Anaheim SpinCo B.V., and Shareholder Representative Services LLC acting as representative and attorney-in-fact of the Company Participating Equityholders. The agreement sets out the terms by which BioMarin will acquire all shares of Alesta via the Share Purchase.

The filing states that closing of the transaction is conditioned on, among other things, the absence of any temporary restraining order, injunction, or other legal order that would make the Share Purchase illegal or otherwise prohibit its completion, the pre-closing transfer of certain Alesta assets and businesses to SpinCo, and other customary conditions specified in the Purchase Agreement. The Purchase Agreement also contains customary termination rights for both BioMarin and Alesta, according to the filing.

The filing notes that the Purchase Agreement includes representations, warranties, agreements, and covenants from both parties, including customary operating restrictions on Alesta's business conduct and cooperation provisions that apply until completion or termination of the Share Purchase. The filing cautions that the representations and warranties "were made only for the purposes of the Purchase Agreement and solely for the benefit of the parties" and that investors should not rely on them "as characterizations of the actual state of facts or condition of BioMarin, Alesta or any of their respective subsidiaries, affiliates or businesses." The filing also notes that statements about anticipated timing and other future events are the company's own forward-looking statements and are subject to its cautionary language, with actual results potentially differing materially from those anticipated.

What Was Disclosed

BioMarin disclosed entry into a Share Purchase Agreement to acquire Alesta Therapeutics B.V. for $275 million upfront plus up to $215 million in development milestone payments, with closing expected in the third quarter of 2026, subject to specified conditions.